EI
ABEO icon

EAM Investors’s Abeona Therapeutics ABEO Stock Holding History

EAM Investors’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-97,809
Closed -$490K – 233
2023
Q4 		$490K Buy
+97,809
New +$430K 0.09% 230
2018
Q1 		– Sell
-6,681
Closed -$2.65M – 283
2017
Q4 		$2.65M Buy
6,681
+794
+13% +$328K 0.47% 75
2017
Q3 		$2.51M Buy
+5,887
New +$1.58M 0.33% 109

Other funds holding ABEO

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

EAM Investors's ABEO Position: Q1 2024 in Review

EAM Investors sold out of Abeona Therapeutics (ABEO) in Q1 2024, closing a stake of 97,809 shares — an estimated $490K sold.

EAM Investors first reported a position in ABEO in Q3 2017 and held it in 3 quarters. The position peaked at $2.65M in Q4 2017. 56 funds tracked by Wall St. Rank hold ABEO as of Q1 2024.

  • EAM Investors reported no remaining Abeona Therapeutics position as of Q1 2024 after selling out during the quarter.
  • EAM Investors sold 97,809 Abeona Therapeutics shares in Q1 2024, an estimated $490K.
  • EAM Investors first reported a position in Abeona Therapeutics in Q3 2017 and held it in 3 quarters.
  • EAM Investors's Abeona Therapeutics position peaked at $2.65M in Q4 2017.
  • 56 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2024.

Based on EAM Investors's 13F filing for Q1 2024, filed 13 May 2024.